ep 4: oncology morning commute: targeting her2, her3, and trop2 in nsclc
Published 2 years ago • 11 plays • Length 26:57Download video MP4
Download video MP3
Similar videos
-
56:23
are you prepared for the new wave of adcs in nsclc? targeting her2, her3, trop2, and others
-
58:27
addressing key targets in advanced nsclc: her2-, her3-, and trop2-targeted therapies
-
58:30
the potential of her2-, her3-, and trop2-targeted therapies to address unmet needs in advanced nsclc
-
1:45
strategies to target her2 in lung cancer
-
0:34
rational for her3-targeting in nrg1 fusion-positive nsclc
-
0:42
targeting programmed cell death to transform cancer therapies
-
4:27
study of immunotherapy combinations for patients with her2-positive metastatic breast cancer
-
3:58
antibody drug conjugates in lung cancer
-
2:22
dr. pennell on the evolution of targeting her2 in lung cancer
-
26:34
ep3 : oncology morning commute: her2 crc therapies in clinical practice
-
3:32
biomarker testing for adcs
-
1:20
dr. corcoran on targeting her2 amplification in crc
-
2:45
therapeutic advances in targeting her2 alterations in nsclc & remaining challenges
-
1:10
dr. bunn on targeting her3 in nsclc
-
1:12
dr. yorio on t-dm1 in her2-mutant lung cancer treatment
-
6:31
gracecast - treatment options for patients with advanced nsclc and a her2- erbb2 mutation
-
0:49
systemic therapies shown to be effective in her2-positive breast cancer
-
2:07
recommendations for her2 testing in metastatic breast cancer
-
0:50
exploring potential her2-positive breast cancer treatments for the future